We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

137 hedge funds and large institutions have $1.17B invested in Eagle Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more call options, than puts

Call options by funds: $17.5M | Put options by funds: $6.33M

75% more capital invested

Capital invested by funds: $667M → $1.17B (+$502M)

75% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 28

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

18% more funds holding

Funds holding: 116 → 137 (+21)

9% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 33

Holders
137
Holders Change
+21
Holders Change %
+18.1%
% of All Funds
3.65%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
49
Increased
36
Reduced
33
Closed
28
Calls
$17.5M
Puts
$6.33M
Net Calls
+$11.2M
Net Calls Change
+$7.1M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$38.2M
2
First Eagle Investment Management
First Eagle Investment Management
New York
+$31.5M
3
BFA
BlackRock Fund Advisors
California
+$19.8M
4
PC
PointState Capital
New York
+$16.9M
5
PA
Perceptive Advisors
New York
+$13.6M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$23.4M
2
PAI
ProQuest Associates IV
Florida
-$22M
3
GPP
Great Point Partners
Connecticut
-$21.3M
4
CCM
Consonance Capital Management
New York
-$18.7M
5
GE
General Electric
Ohio
-$13.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Thrivent Financial for Lutherans
101
Thrivent Financial for Lutherans
Minnesota
$290K +$229K +4,140 New
ASRS
102
Arizona State Retirement System
Arizona
$287K +$227K +4,100 New
PPA
103
Parametric Portfolio Associates
Washington
$283K +$224K +4,043 New
AIA
104
Affinity Investment Advisors
California
$274K +$217K +3,917 New
LSERS
105
Louisiana State Employees Retirement System
Louisiana
$245K +$194K +3,500 New
UBS AM
106
UBS AM
Illinois
$245K +$194K +3,500 New
LTFS
107
Ladenburg Thalmann Financial Services
Florida
$231K -$2.77K -50 -1%
MFIMFI
108
Mesirow Financial Investment Management - Fixed Income
Illinois
$222K +$176K +3,170 New
BFM
109
Boothbay Fund Management
New York
$220K +$174K +3,146 New
BCM
110
Bayesian Capital Management
New York
$212K +$168K +3,032 New
Public Employees Retirement Association of Colorado
111
Public Employees Retirement Association of Colorado
Colorado
$205K – – –
TRSOTSOK
112
Teachers Retirement System of the State of Kentucky
Kentucky
$175K +$139K +2,500 New
SG Americas Securities
113
SG Americas Securities
New York
$166K +$132K +2,375 New
PAM
114
Paradigm Asset Management
New York
$161K +$127K +2,300 New
MSA
115
Mason Street Advisors
Wisconsin
$115K +$91K +1,642 New
Bank of America
116
Bank of America
North Carolina
$113K -$73.6K -1,328 -45%
BNP Paribas Financial Markets
117
BNP Paribas Financial Markets
France
$83.5K +$46.3K +836 +234%
PI
118
PineBridge Investments
New York
$71K +$56.2K +1,014 New
US Bancorp
119
US Bancorp
Minnesota
$66K +$4.71K +85 +10%
BlackRock
120
BlackRock
New York
$54K +$3.05K +55 +8%
AG
121
Advisor Group
Arizona
$42K – – –
PCM
122
Prelude Capital Management
New York
$30K +$23.8K +430 New
Zurich Cantonal Bank
123
Zurich Cantonal Bank
Switzerland
$27K – – –
LIA
124
LS Investment Advisors
Michigan
$25K +$19.7K +356 New
NFG
125
Next Financial Group
Texas
$14K +$11.1K +200 New
3 4
5
6 7

EGRX Hedge Fund Activity: Q3 2016 in Review

137 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2016, worth a combined $1.17B — up 75% from $667M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new EGRX positions and 28 closed out — a net gain of 21 holders — while 36 added to existing stakes and 33 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $38.2M. The largest seller was Morgan Stanley, cutting an estimated $23.4M.

  • 137 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2016, up from 116 in Q2 2016.
  • Funds reported $1.17B of Eagle Pharmaceuticals, Inc. stock for Q3 2016, up 75% quarter-over-quarter.
  • 49 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2016 and 28 closed out, a net change of +21 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2016 was Victory Capital Management, an estimated $38.2M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q3 2016 was Morgan Stanley, an estimated $23.4M sold.

Based on aggregated 13F filings for Q3 2016.